Oruka Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
/ 
Frequently asked questions
To buy Oruka Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Oruka Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Oruka Therapeutics Inc. is ORKA:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Oruka Therapeutics Inc. has its primary listing on NASDAQ. You can trade Oruka Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Oruka Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Oruka Therapeutics Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Oruka Therapeutics Inc..